常茂生物(00954.HK)中期净利润增长约200%至4252.8万元
格隆汇8月8日丨常茂生物(00954.HK)公布中期业绩,截至2019年6月30日止六个月,公司实现收入2.98亿元人民币(下同),同比减少6.1%;毛利9485.5万元,同比增长58.4%;公司股东应占利润4252.8万元,同比增长199.56%;基本每股盈利0.080元;不派中期股息。
公告表示,2019年上半年,集团生产经营稳定,项目建设进展顺利,特别是常州工厂顺酐改造项目的完成,以及经营管理上的提升逐见成效,推动经济效益持续增长。集团销售收入较去年同期下降约6%;归属于公司权益持有人的净利润比去年同期增长约200%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.